HK Stock MarketDetailed Quotes

08329 NEP INTERLONG

Watchlist
  • 0.135
  • -0.010-6.90%
Market Closed Nov 8 16:08 CST
226.53MMarket Cap6.43P/E (TTM)

About NEP INTERLONG Company

Enterprise mission Adhering to the concept of “health becomes the future”, Haiwang Intron uses modern biotechnology and pharmaceutical technology as an innovation platform to develop cytokine protein therapeutics and preventive biological products, create core competitiveness represented by independent intellectual property product development and specialized marketing capabilities, gradually establish a leading position in the domestic market, and at the same time develop an international strategy. Huge market potential opens up unlimited business opportunities In the past, the level of investment in medical expenses or disease prevention in China was far lower than in developed countries. However, vigorous economic development has improved people's lives, so the focus on health is also higher than before. Coupled with the problem of population aging, domestic demand for medicines has increased dramatically. Furthermore, China's biotechnology is at a level similar to international technology, has a good momentum of development, and the prospects are very optimistic. The company believes that China's biopharmaceutical industry will become more mature, bringing unlimited business opportunities to the company. Grasp technological trends and excellent R&D capabilities Aquaman Interlong has strong scientific research capabilities, and the R&D team has professional knowledge and rich R&D experience. The company has independent research and development capabilities. The pilot plant for R&D meets GMP standards, and each laboratory is equipped with advanced research facilities and testing instruments. The company has also cooperated with many powerful professional biotechnology companies or research institutes and achieved good results. The biotechnology drugs developed and produced by the company have the advantages of low cost, high efficiency, safety and reliability, and have great potential for development. Furthermore, for the core technology of the new product, the company has obtained 1 core technology invention patent, and is currently applying for invention patents for a number of technologies. In the next three years, the company will launch several new products with independent intellectual property rights, and the market prospects are broad. Enjoy brand advantages without fear of market competition Haiwang Intron's products use Haiwang Pharmaceutical's licensed trademark “Haiwang”, which is a well-known trademark in China. The brand has established excellent reputation and popularity in China over the years. The brand advantage helps increase the market's acceptance of the various new drugs introduced by the company in the future, and greatly enhances the company's competitiveness. Strict quality control by outstanding enterprise professionals The company's management has a professional background, rich corporate experience, in-depth understanding of industry development, and looking forward to the company's future direction and strategy. At the same time, they also pay attention to employee training and actively recruit industry professionals. The company knows that product quality is as important as scientific research, and strictly controls quality, so the products have a good reputation in China. The company's current production complies with GMP standards and operating guidelines, and strict product monitoring is implemented. Looking forward to the future, building the future With strong R&D capabilities, professional marketing methods, strict quality control and excellent enterprise management, Haiwang Intron has accumulated rich management experience in China, established a certain level of popularity, and successfully sought considerable market coverage. The company will continue to develop its past, expand the scale of production and enhance its R&D capabilities, combine advanced technology, increase the variety of products, and actively expand its business to overseas markets to achieve future health for mankind.

Company Profile

Symbol08329
Company NameNEP INTERLONG
ISINCNE100000775
Listing DateSep 12, 2005
Issue Price0.33
Shares Offered236.67M share(s)
FoundedNov 15, 1994
Registered AddressChina
Chairmanfeng zhang
Secretaryjianbofenghuisen huang
Audit InstitutionGrant Thornton (Hong Kong) Certified Public Accountants Limited
Company CategoryMainland registration of Mainland Individuals control
Registered Office1702, Haiwang Yinhe Science and Technology Building, No. 1, Keizhong 3rd Road, Maling Community, Yuehai Street, Nanshan District, Shenzhen
Head Office and Principal Place of Business43rd Floor, Taikoo Place, 979 King's Road, Quarry Bay, Hong Kong
Fiscal Year Ends12-31
Employees1471
MarketGEM
Phone(86)75526411869
Fax(86)75526416299-8014
Emailhjb@interlong.com; auditcommittee@interlong.com
Business The company and its subsidiaries are mainly engaged in research and development, production and sale of pharmaceuticals and health foods.

Company Executives

  • Name
  • Position
  • Salary
  • feng zhang
  • Chairman of the Board, Executive Director, Chairman of the Nomination Committee, Remuneration Committee Members, Chief Inspector, Authorized Representative
  • 100.00K
  • jianbo huang
  • Executive Director, Deputy General Manager, Head of Finance, Joint Company Secretary, Board Secretary, Authorized Representative
  • 624.00K
  • xiaoguang zhang
  • Executive Director
  • 639.00K
  • yifei zhang
  • Non-executive Directors
  • 100.00K
  • lin yu
  • Non-executive Directors, Audit Committee Members
  • 100.00K
  • rui jin
  • Non-executive Directors
  • 100.00K
  • yongfa yi
  • Independent Non-Executive Director, Chairman of the Audit Committee, Remuneration Committee Member, Nomination Committee Members
  • 212.00K
  • jiayang pan
  • Independent Non-Executive Director, Remuneration Committee Chairman, Nomination Committee Members, Audit Committee Members
  • 106.00K
  • jianzhou zhang
  • Independent Non-Executive Director, Nomination Committee Members
  • 100.00K
  • chuxiong xiong
  • Chairman of the Supervisory Board, Independent Auditors
  • --
  • ge jin
  • Auditors
  • --
  • yang cao
  • Employee Representative Supervisor
  • --
  • huisen feng
  • Joint Company Secretary
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data